Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Encore Capital Group
ECPG
$1.98B
| $20.2M | ﹤0.01% |
371,916
+39,214
| +12% | +$1.89M |
|
|
CADE
1252
DELISTED
Cadence Bank
CADE
| $20.2M | ﹤0.01% |
471,326
+15,899
| +3% | +$630K |
|
1253
Palomar
PLMR
$3.47B
| $20.2M | ﹤0.01% |
149,826
+7,049
| +5% | +$860K |
|
|
LVLN
1254
State Street SPDR S&P Leveraged Loan ETF
LVLN
$49.6M
| $20.2M | ﹤0.01% |
+800,000
| New | +$20.1M |
|
1255
Tandem Diabetes Care
TNDM
$1.63B
| $20.2M | ﹤0.01% |
917,927
-272,200
| -23% | -$4.91M |
|
1256
ManpowerGroup
MAN
$2.62B
| $20.1M | ﹤0.01% |
675,909
+91,710
| +16% | +$2.87M |
|
1257
Tanger
SKT
$4.43B
| $20.1M | ﹤0.01% |
602,088
+94,343
| +19% | +$3.15M |
|
1258
CALL
Best Buy
BBY
$17.6B
| $20.1M | ﹤0.01% |
300,000
+200,000
| +200% | +$15.3M |
|
1259
The Greenbrier Companies
GBX
$1.43B
| $20.1M | ﹤0.01% |
429,487
-193,177
| -31% | -$8.66M |
|
1260
LiveRamp
RAMP
$2.3B
| $20M | ﹤0.01% |
682,367
-39,212
| -5% | -$1.13M |
|
1261
Hormel Foods
HRL
$13.4B
| $20M | ﹤0.01% |
844,330
-1,166,594
| -58% | -$27.2M |
|
1262
Affirm
AFRM
$25.7B
| $19.9M | ﹤0.01% |
267,628
-36,744
| -12% | -$2.64M |
|
|
GTLS
1263
DELISTED
Chart Industries
GTLS
| $19.9M | ﹤0.01% |
96,446
-6,819
| -7% | -$1.38M |
|
1264
Kirby Corp
KEX
$7B
| $19.8M | ﹤0.01% |
180,023
-6,237
| -3% | -$634K |
|
1265
CubeSmart
CUBE
$9.2B
| $19.8M | ﹤0.01% |
548,255
-36,457
| -6% | -$1.39M |
|
1266
PUT
Sunrun
RUN
$2.42B
| $19.7M | ﹤0.01% |
1,072,200
-2,409,000
| -69% | -$46.2M |
|
1267
Amdocs
DOX
$6.1B
| $19.7M | ﹤0.01% |
244,117
+21,171
| +9% | +$1.7M |
|
1268
Casey's General Stores
CASY
$30.7B
| $19.5M | ﹤0.01% |
35,312
-123,794
| -78% | -$68.1M |
|
|
EXAS
1269
DELISTED
Exact Sciences
EXAS
| $19.5M | ﹤0.01% |
191,743
-101,033
| -35% | -$8.11M |
|
1270
iShares US Home Construction ETF
ITB
$2.4B
| $19.3M | ﹤0.01% |
200,186
+46,511
| +30% | +$4.7M |
|
1271
Sociedad Química y Minera de Chile
SQM
$20.6B
| $19.1M | ﹤0.01% |
277,717
-539,506
| -66% | -$29.7M |
|
1272
PUT
Labcorp
LH
$26.1B
| $19M | ﹤0.01% |
+75,900
| New | +$20.2M |
|
1273
PUT
Waters Corp
WAT
$40.7B
| $19M | ﹤0.01% |
50,000
| – | – |
|
1274
CALL
Abercrombie & Fitch
ANF
$5.24B
| $18.9M | ﹤0.01% |
+150,000
| New | +$13.1M |
|
1275
Harmony Gold Mining
HMY
$12.2B
| $18.9M | ﹤0.01% |
948,683
+670,178
| +241% | +$12.5M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.